-
Chromosome segregation in SCNT oocytes Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-05-14 Louise Lloyd
The possibility of men in same-sex relationships and people who do not have their own eggs having biological children has been advanced by new research into in vitro gametogenesis, in which functional haploid gametes are generated from diploid somatic cells. In previous, proof-of-principle experiments showing that haploidy in somatic cell genomes can be induced experimentally by premature cell division
-
Overcoming barriers in cancer care for gender minorities Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-05-13 David J. Benjamin, Omid Yazdanpanah, Arash Rezazadeh Kalebasty
As the population of gender minorities grows in the setting of rising incidence of cancers globally, health-care professionals and institutions must be prepared to provide inclusive care. Individual-level training as well as institutional-level efforts on gender identity data collection and creation of inclusive clinical spaces could help mitigate health-care disparities.
-
We all get erections — de-gendering sexual arousal dysfunction in the ICD Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-05-08 Lucy Greenwald, Daniel R. Dickstein, Barbara Chubak, Deborah C. Marshall
-
Breaking the silence: normalizing receptive anal intercourse for patients, for people and for myself Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-05-08 Daniel R. Dickstein
The lack of information and discussion on receptive anal intercourse (RAI) perpetuates the stigma. Normalizing RAI and empowering individuals to embrace their sexuality without shame or judgement requires us to confront biases, foster dialogue and break the silence.
-
Centralization of care for rare genetic syndromes associated with cancer: improving outcomes and advancing research on VHL disease Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-05-08 Alessandro Larcher, Federico Belladelli, Francesco Cei, Chiara Re, Isaline Rowe, Francesco Montorsi, Umberto Capitanio, Andrea Salonia
-
Asexuality: the invisible orientation Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-05-07 Sarah Cosgriff, Stella Schneckenburger
Asexuality is often neglected in education and conversations around sexuality, making it essentially an ‘invisible orientation’. This lack of knowledge is associated with harmful misconceptions, which need challenging within the medical profession and in the general population to ensure inclusion of people who identify on the asexual spectrum.
-
Elevated periprostatic androgens, sneaky testosterone and its implications Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-05-07 Masoud Bitaraf, Ranjith Ramasamy, Sanoj Punnen, Nima Sharifi
-
Current and emerging strategies to curb antibiotic-resistant urinary tract infections Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-05-07 Aaron Simoni, Laura Schwartz, Guillermo Yepes Junquera, Christina B. Ching, John David Spencer
-
The evolving treatment landscape of metastatic urothelial cancer Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-05-03 Giandomenico Roviello, Matteo Santoni, Guru P. Sonpavde, Martina Catalano
-
Von Hippel–Lindau protein signalling in clear cell renal cell carcinoma Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-05-02 Chengheng Liao, Lianxin Hu, Qing Zhang
-
Strengthening preclinical testing to increase safety in surgical mesh Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-05-01 Nicholas T. H. Farr, Victoria L. Workman, Christopher R. Chapple, Sheila MacNeil, Cornelia Rodenburg
Inflammatory and fibrotic responses to polypropylene mesh led to the withdrawal of this practice for treatment of stress urinary incontinence and pelvic organ prolapse in women in some countries. Improved material testing has been urged. We report poor responses of polypropylene mesh to repeated mechanical distension and macrophage interrogation. These results from preclinical in vitro testing show
-
From biology to the clinic — exploring liver metastasis in prostate cancer Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-04-26 Xudong Ni, Yu Wei, Xiaomeng Li, Jian Pan, Bangwei Fang, Tingwei Zhang, Ying Lu, Dingwei Ye, Yao Zhu
-
Influence of substance use on male reproductive health and offspring outcomes Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-04-25 Jamie O. Lo, Jason C. Hedges, Wesley H. Chou, Kylie R. Tager, Ian D. Bachli, Olivia L. Hagen, Susan K. Murphy, Carol B. Hanna, Charles A. Easley
The prevalence of substance use globally is rising and is highest among men of reproductive age. In Africa, and South and Central America, cannabis use disorder is most prevalent and in Eastern and South-Eastern Europe, Central America, Canada and the USA, opioid use disorder predominates. Substance use might be contributing to the ongoing global decline in male fertility, and emerging evidence has
-
Bladder cancer variants — one disease with many faces Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-04-22 Bogdan Czerniak
Bladder cancer progression to microscopically distinct variants such as sarcomatoid, small cell, micropapillary and plasmacytoid is associated with more aggressive clinical behaviour than conventional carcinoma. Advances in molecular profiling led to the identification of molecular subtypes of bladder cancer and provided insights into disease progression to aggressive variants.
-
EAU à la mode Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-04-17 Louise Lloyd
Urologists from around the world congregated at the 39th Annual Congress of the European Association of Urology (EAU), which took place in Paris, France, between 5 and 8 April 2024. In the Olympic host city, the Olympian efforts of clinicians and researchers in the field to improve knowledge and understanding and, ultimately, patient outcomes were evident around the convention centre. Day 1 of the
-
The evolving landscape of monogenic nephrolithiasis and therapeutic innovations Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-04-17 Chen-Han Wilfred Wu, Yu-Ren Huang, Donald Bodner, Fredrick R. Schumacher, Michelle Baum, Friedhelm Hildebrandt
Monogenic causes account for up to 20% of nephrolithiasis instances and are crucial for developing targeted treatments. Whole-exome sequencing, genome-wide association, candidate gene, and in vitro and animal functional studies are crucial to identify these mutations. Therapies targeting monogenic variants, such as RNA-interference-based treatments, have been successfully used to treat monogenic disorders
-
Patient-reported toxic effects of hypofractionated versus conventional RT Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-04-16 Maria Chiara Masone
Post-prostatectomy radiotherapy (RT) is a common second-line treatment for patients with prostate cancer. In the phase III randomized NRG-GU003 trial, hypofractionated postprostatectomy RT (HYPORT) was compared with conventionally fractionated postprostatectomy RT (COPORT) in terms of patient-reported genitourinary (GU) and gastrointestinal (GI) symptoms in patients with prostate cancer who had received
-
Safe delivery of ICI therapy through sub-urothelial injection Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-04-16 Maria Chiara Masone
Systemic treatment with the human monoclonal anti-PDL1 antibody durvalumab showed benefit in several cancers. In a phase Ib study published in BJU International, the safety of sub-urothelial durvalumab injection was assessed in patients with non-metastatic muscle-invasive or non-muscle-invasive bladder cancer planned to receive radical cystectomy. Overall, 11 patients received sub-urothelial injection
-
HRQoL in patients receiving EV versus chemotherapy Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-04-16 Maria Chiara Masone
In the phase III EV-301 trial, enfortumab vedotin (EV) has been shown to increase overall survival compared with chemotherapy in patients with metastatic urothelial carcinoma who had previously received chemotherapy and experienced disease progression after treatment with PD1 or PDL1 inhibitors. In a study published in European Urology, patient-reported outcome (PRO) analysis of health-related quality
-
Unlocking ferroptosis in prostate cancer — the road to novel therapies and imaging markers Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-04-16 Pham Hong Anh Cao, Abishai Dominic, Fabiola Ester Lujan, Sanjanaa Senthilkumar, Pratip K. Bhattacharya, Daniel E. Frigo, Elavarasan Subramani
-
A CAF subpopulation promotes LVI in early-stage bladder cancer Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-04-15 Maria Chiara Masone
In a new article published in Cancer Cell, a subset of cancer-associated fibroblasts (CAFs) was shown to have a crucial role in promoting lymphovascular invasion (LVI) in early-stage bladder cancer. In this study, LVI analysis in tissue samples from patients with bladder cancer showed that LVI in patients with early-stage disease was associated with increased rates of lymph node (LN) metastases and
-
The case for centralization of care in penile cancer — respecting geographical needs Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-04-15 Giuseppe Basile, Andrea Necchi, Gagan Prakash, Karima Oualla, Philippe E. Spiess, Peter A. S. Johnstone
Centralization of care for penile cancer has been underscored in the 2023 updated EAU–ASCO guidelines. Expertise consolidation enhances patient care, addressing penile cancer complexities from diagnosis to treatment. Centralization initiatives, like the European Reference Networks, and dedicated scientific societies have crucial roles in guiding centralized care pathways to ultimately improve patient
-
Signatures of metabolic diseases on spermatogenesis and testicular metabolism Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-03-25 David F. Carrageta, Sara C. Pereira, Rita Ferreira, Mariana P. Monteiro, Pedro F. Oliveira, Marco G. Alves
-
Robots learning to imitate surgeons — challenges and possibilities Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-03-21 Samuel Schmidgall, Ji Woong Kim, Axel Krieger
-
Overcoming antibiotic resistance in complicated UTI Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-03-14 Maria Chiara Masone
Complicated urinary tract infection (UTI) is a debilitating condition often resulting in patient hospitalization and consequent high health-care costs. β-lactam antibiotics such as cephalosporins are often used to treat complicated UTI, but a widespread resistance to antibiotics hampers the eradication of these infections. The phase III, randomized, double-blind, double-dummy trial CERTAIN-1 was conducted
-
The ins and outs of penile erection Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-03-14 Louise Lloyd
New discoveries concerning the function of fibroblasts in penile erection have improved our understanding of this physiological process. In humans, fibroblasts are the largest cell population in the corpora cavernosa, but until now their function had not been elucidated. “We study perivascular fibroblasts in the context of fibrosis in the central nervous system and I was curious about their physiological
-
Robotic kidney transplantation Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-03-13 Giuseppe Basile, Alessio Pecoraro, Andrea Gallioli, Angelo Territo, Camille Berquin, Jorge Robalino, Alejandra Bravo, Jorge Huguet, Óscar Rodriguez-Faba, Pavel Gavrilov, Carmen Facundo, Lluis Guirado, Josep Maria Gaya, Joan Palou, Alberto Breda
-
Diversifying editorial boards to mitigate the global burden of genitourinary cancers Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-03-01 David J. Benjamin, Zhaohui Arter, Nataliya Mar, Arash Rezazadeh Kalebasty
The growing global burden of genitourinary cancers is disproportionately shouldered by low- and middle-income countries. Medical journals offer an avenue for discourse among different stakeholders to strategize and identify solutions. Thus, achieving diversity in this context is crucial to put together a heterogeneous group of stakeholders with diverse personal and cultural experiences as well as distinct
-
Targeting histone modifiers in bladder cancer therapy — preclinical and clinical evidence Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-02-19 Shiyu Zhang, Tianhai Lin, Xingyu Xiong, Chong Chen, Ping Tan, Qiang Wei
-
The evolving management of small renal masses Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-02-16 Yuzhi Wang, Mohit Butaney, Samantha Wilder, Khurshid Ghani, Craig G. Rogers, Brian R. Lane
-
Sun, sea, sex and spaghetti as the ESSM hits Bari Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-02-16 Annette Fenner
Delegates were treated to a fantastic menu of both science and gastronomy as the European Society for Sexual Medicine (ESSM) Congress met in Bari, southern Italy, 9–11 February 2024. Unsurprisingly, Italy topped the list of attendees at this cosmopolitan meeting, which saw 650 delegates converge from across the world to discuss the latest research and topics in sexual medicine. A total of 72 scientific
-
ADT intensification to treat biochemically recurrent prostate cancer Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-02-14 Maria Chiara Masone
In the randomized phase III, open-label trial PRESTO, the effect of potentiating androgen deprivation therapy (ADT) on improving oncological outcomes in patients with biochemically recurrent prostate cancer (BRPC) was assessed. Patients with BRPC (n = 503) and a short PSA doubling time (≤9 months) were enrolled and randomized 1:1:1 to receive ADT (control arm), ADT + apalutamide, or ADT + apalutamide + abiraterone
-
A new rapid point-of-care test for N. gonorrhoeae Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-02-14 Maria Chiara Masone
The lack of a rapid, cheap point-of-care test to diagnose infection with Neisseria gonorrhoeae has led to overuse of antibiotics and syndromic treatment. In a study published in The Lancet, the diagnostic performance of a new N. gonorrhoeae lateral flow assay (NG-LFA), which had shown promising results in frozen clinical specimens, was assessed in male patients with urethral discharges (n = 200) and
-
Mellow yellow: BilR reduces bilirubin to urobilinogen Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-02-14 Louise Lloyd
Researchers have identified the enzyme, now called bilirubin reductase (BilR), that converts bilirubin to urobilinogen, giving urine its distinctive yellow colour. The reduction of bilirubin to urobilinogen is performed solely by the gut microbiota; however, hitherto the gut microbial enzyme that reduces bilirubin to urobilinogen had not been discovered. Using a fluorescence assay on various bacteria
-
First-morning urine samples to study the urobiome Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-02-14 Maria Chiara Masone
The urinary microbiome (urobiome) is emerging as a new contributing factor in determining bladder cancer risk, but data from different studies are conflicting, owing to the lack of standardization. In a new study published in European Urology Open Science, a urobiome analysis was conducted in 48 patients undergoing transurethral resection of bladder tumour, through the next-generation sequencing analysis
-
RNA N6-methyladenosine modifications in urological cancers: from mechanism to application Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-02-12 Lei Yang, Jianming Ying, Qian Tao, Qian Zhang
-
Mechanisms of oxidative stress in interstitial cystitis/bladder pain syndrome Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-02-07 Ashu Mohammad, Mallory A. Laboulaye, Chen Shenhar, Amy D. Dobberfuhl
-
Molecular profile of bladder cancer progression to clinically aggressive subtypes Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-02-06 Charles C. Guo, Sangkyou Lee, June G. Lee, Huiqin Chen, Michael Zaleski, Woonyoung Choi, David J. McConkey, Peng Wei, Bogdan Czerniak
-
Supplementary selenium and vitamin E in non-muscle-invasive bladder cancer Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-02-05 Shaun J. Trecarten, Robert S. Svatek
In the SELENIB trial, selenium and vitamin E were compared with placebo as chemoprevention for non-muscle-invasive bladder cancer (NMIBC). No difference versus placebo was observed in recurrence-free interval (RFI) with selenium, but vitamin E was associated with worse RFI. Selenium and vitamin E cannot be recommended in chemoprevention for NMIBC. Furthermore, patients with NMIBC taking supplemental
-
The complex interplay of modifiable risk factors affecting prostate cancer disparities in African American men Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-02-02 Jabril R. Johnson, Nicole Mavingire, Leanne Woods-Burnham, Mya Walker, Deyana Lewis, Stanley E. Hooker, Dorothy Galloway, Brian Rivers, Rick A. Kittles
-
The yin and yang of chromosomal instability in prostate cancer Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-02-02 Marc Carceles-Cordon, Jacob J. Orme, Josep Domingo-Domenech, Veronica Rodriguez-Bravo
-
Management of patients with muscle-invasive bladder cancer with clinical evidence of pelvic lymph node metastases Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-01-31 Elisabeth Grobet-Jeandin, Louis Lenfant, Ugo Pinar, Jérôme Parra, Pierre Mozer, Raphaele Renard-Penna, Constance Thibault, Morgan Rouprêt, Thomas Seisen
-
Pembrolizumab plus enfortumab vedotin in urothelial cancer Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-01-24 Matteo Santoni, Hideki Takeshita, Francesco Massari, Aristotelis Bamias, Linda Cerbone, Ondrej Fiala, Veronica Mollica, Sebastiano Buti, Angela Santoni, Joaquim Bellmunt
The combination of pembrolizumab and enfortumab vedotin shows promise as a first-line therapy for advanced urothelial carcinoma. Enfortumab vedotin targets nectin-4, in turn enhancing T cell and natural killer cell activity, inhibiting immunosuppressive pathways and impeding tumour evasion. This synergy with pembrolizumab shows potential in enhancing immunotherapy for these patients.
-
Sperm activity affected by endometriosis Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-01-22 Annette Fenner
Endometriosis-associated infertility is regulated via extracellular vesicles, with a direct effect on sperm activity, according to data published in the Journal of Cellular Physiology.
-
A clinical overview of people living with HIV and genitourinary cancer care Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-01-18 Chalairat Suk-Ouichai, Anna E. Coghill, Matthew B. Schabath, Julian A. Sanchez, Jad Chahoud, Andrea Necchi, Anna R. Giuliano, Philippe E. Spiess
-
Gut microbiome’s effect on immunotherapy response Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-01-16 Maria Chiara Masone
The gut microbiome has been shown to have a role in mediating the anticancer activity of immune checkpoint inhibitors. In a new study published in European Urology, the composition and role of the stool microbiome was assessed in patients with muscle-invasive bladder cancer who received pembrolizumab in the PURE-01 trial. Different microbial species were enriched in respondents versus non-respondents
-
Urinoids — a new tool to study bladder cancer Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-01-16 Maria Chiara Masone
Current treatments for bladder cancer are only effective in a limited percentage of patients, indicating that personalized treatment based on individual tumour characteristics is needed. In a new study published in the British Journal of Cancer, bladder cancer organoids were established non-invasively from patients’ urine (urinoids). These urinoids recapitulated the histological features and the genetic
-
Effect of bariatric surgery on sexual function Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-01-16 Maria Chiara Masone
Men with obesity can experience several medical and psychological issues, including sexual dysfunction and a reduction of testosterone levels. Bariatric surgery has been proposed to ameliorate sexual function in these men, but data are scarce. In a prospective study, hormonal levels, semen parameters and sexual libido were assessed in 20 men before and 6 months after bariatric surgery. No differences
-
Focusing on male infertility Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-01-16
The burden of male infertility is often unrecognized and its causes are poorly understood. Efforts to increase awareness and understanding are being undertaken to improve fertility outcomes and overall health for affected men.
-
Being a non-native English speaker in science and medicine Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-01-15 Sigrid V. Carlsson, Sandro C. Esteves, Elisabeth Grobet-Jeandin, Maria Chiara Masone, Maria J. Ribal, Yao Zhu
-
The effect of red blood cell disorders on male fertility and reproductive health Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-01-03 Bryan D. Naelitz, Prajit S. Khooblall, Neel V. Parekh, Sarah C. Vij, Seth J. Rotz, Scott D. Lundy
-
Shared decision-making before prostate cancer screening decisions Nat. Rev. Urol. (IF 15.3) Pub Date : 2024-01-02 Kelly R. Pekala, Daniela K. Shill, Mia Austria, Aisha T. Langford, Stacy Loeb, Sigrid V. Carlsson
-
Intratumoural immunotherapy plus focal thermal ablation for localized prostate cancer Nat. Rev. Urol. (IF 15.3) Pub Date : 2023-12-19 Denis Séguier, Eric S. Adams, Srinath Kotamarti, Vincent D’Anniballe, Zoe D. Michael, Sriram Deivasigamani, Jonathan Olivier, Arnauld Villers, Christopher Hoimes, Thomas J. Polascik
-
Molecular mechanisms of cellular dysfunction in testes from men with non-obstructive azoospermia Nat. Rev. Urol. (IF 15.3) Pub Date : 2023-12-18 Arina Piechka, Sydney Sparanese, Luke Witherspoon, Faraz Hach, Ryan Flannigan
-
Mechanical characteristics of the ureter and clinical implications Nat. Rev. Urol. (IF 15.3) Pub Date : 2023-12-15 Sorcha O’Meara, Eoghan M. Cunnane, Stefanie M. Croghan, Connor V. Cunnane, Michael T. Walsh, Fergal J. O’Brien, Niall F. Davis
-
AUC 23 — top-notch urology in a tropical paradise Nat. Rev. Urol. (IF 15.3) Pub Date : 2023-12-14 Maria Chiara Masone
The outstanding all-inclusive resort Club Med Michès Playa Esmeralda in the Dominican Republic hosted the 2nd edition of the Advances in Urologic Care (AUC) meeting, from 13 to 16 November 2023. After a spectacular first meeting in Bora Bora in 2019, this was the first edition after the lifting of COVID-19 restrictions.
-
Human-relevant urothelial model provides insight into infection strategies and host response Nat. Rev. Urol. (IF 15.3) Pub Date : 2023-12-07 Louise Lloyd
Use of a 3D urine-tolerant human urothelial model (3D-UHU), which recapitulates the crucial features of human urothelium, has enabled characterization and improved understanding of colonization and survival strategies used by uropathogens and commensal bacteria. The results of this study provide insights into strain-specific and species-specific infection strategies and the reciprocal host responses
-
Management and cost of stent encrustation in pregnancy Nat. Rev. Urol. (IF 15.3) Pub Date : 2023-12-04 Francesco Di Bello, Gianluigi Califano, Claudia Collà Ruvolo, Simone Morra, Roberto La Rocca, Massimiliano Creta, Luigi Napolitano, Nicola Longo, Giuseppe Celentano
Ureteral stents are useful devices for urological management in pregnancy. However, stent encrustation occurs in up to 13% of patients and is related to increased indwelling time. Stent encrustation can be harmful for both the mother and the fetus, increasing their morbidity and mortality. Thus, whether prevention or cure is more cost effective is pertinent.
-
Clinical application of bladder MRI and the Vesical Imaging-Reporting And Data System Nat. Rev. Urol. (IF 15.3) Pub Date : 2023-11-30 Valeria Panebianco, Alberto Briganti, Thierry N. Boellaard, James Catto, Eva Comperat, Jason Efstathiou, Antoine G. van der Heijden, Gianluca Giannarini, Rossano Girometti, Laura Mertens, Mitsuru Takeuchi, Valdair F. Muglia, Yoshifumi Narumi, Giacomo Novara, Martina Pecoraro, Morgan Roupret, Francesco Sanguedolce, Daniele Santini, Shahrokh F. Shariat, Giuseppe Simone, Hebert A. Vargas, Sungmin Woo
Diagnostic work-up and risk stratification in patients with bladder cancer before and after treatment must be refined to optimize management and improve outcomes. MRI has been suggested as a non-invasive technique for bladder cancer staging and assessment of response to systemic therapy. The Vesical Imaging-Reporting And Data System (VI-RADS) was developed to standardize bladder MRI image acquisition
-
Generative AI in scientific publishing: disruptive or destructive? Nat. Rev. Urol. (IF 15.3) Pub Date : 2023-11-15 Riccardo Bertolo, Alessandro Antonelli
Artificial intelligence (AI) has the potential to revolutionize scientific publishing. The influence of AI could be disruptive or destructive and its influence remains to be seen, but balance between the convenience and accessibility offered by AI-driven tools and the essential skills of deep scientific inquiry and communication needs to be found.